Pharsight

Drugs that contain Zanubrutinib

1. Brukinsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

US11851437 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(9 years from now)

US11884674 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

US11591340 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(13 years from now)

US11701357 BEIGENE Treatment of B cell cancers using a combination comprising Btk inhibitors
Jun, 2039

(15 years from now)

US11911386 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)

US11896596 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)

US11786531 BEIGENE Methods of treating B-cell proliferative disorder
Jan, 2043

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-871) Aug 31, 2024
New Indication(I-936) Mar 07, 2027
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
New Indication(I-874) Sep 14, 2024
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with relaps...

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

Family Patents